Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2022-12-22 00:00:00 ET · period of report 2022-12-21 · accession 0001827672-22-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-12-22 | 2022-12-21 | TARS | Azamian Bobak R. | Pres, CEO, Board COB, Dir | S - Sale | $14.57 | -8,000 | 1.13M | -0.7% | -$116.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-21 | S | D | 8,000 | $14.57 | 1,130,151 | I By the Bobak Azamian Living Trust established April 16, 2018 | — | — | (F2) The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $14.37 to $14.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F3) The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares. |